AURINIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and

NEW YORK–(Enterprise WIRE)–#AUPH–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights legislation agency, reminds investors that a class action lawsuit has been submitted from Aurinia Prescription drugs, Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH) in the United States District Court for the Jap District of New York on behalf of all individuals and entities who obtained or otherwise obtained Aurinia securities between May perhaps 7, 2021 and February 25, 2022, the two dates inclusive (the “Class Period”). Investors have until finally June 14, 2022 to apply to the Court to be appointed as direct plaintiff in the lawsuit.

Click below to take part in the motion.

Aurinia is a biopharmaceutical enterprise that develops and commercializes therapies to take care of different disorders with unmet health care have to have in Japan and the People’s Republic of China (“China”). The Company’s only item is LUPKYNIS, which it offers for the remedy of grownup individuals with energetic lupus nephritis.

All through the Course Period of time, Defendants built materially wrong and deceptive statements about the Company’s business enterprise, operations, and compliance policies. Precisely, Defendants made phony and/or deceptive statements and/or unsuccessful to disclose that: (i) Aurinia was enduring declining revenues (ii) Aurinia’s 2022 product sales outlook for LUPKYNIS would fall nicely quick of expectations (iii) appropriately, the Organization experienced substantially overstated LUPKYNIS’s business prospective buyers (iv) as a result, the Firm experienced overstated its economical position and/or potential clients for 2022 and (v) as a consequence, the Company’s community statements were materially fake and deceptive at all applicable moments.

On February 28, 2022, Aurinia issued a push launch saying its economical success for the quarter and whole yr finished December 31, 2021. Amongst other goods, Aurinia noted a calendar year-around-yr earnings decrease and declared a decrease-than-envisioned revenue outlook for 2022.

On this information, Aurinia’s popular share selling price fell $3.94 for each share, or 24.26%, to near at $12.30 for every share on February 28, 2022.

As a end result of Defendants’ wrongful functions and omissions, and the precipitous decrease in the industry price of the Company’s securities, Plaintiff and other Course customers have suffered sizeable losses and damages.

If you bought or usually obtained Aurinia shares and suffered a decline, are a lengthy-expression stockholder, have info, would like to find out much more about these claims, or have any thoughts regarding this announcement or your legal rights or passions with regard to these issues, be sure to speak to Brandon Walker or Alexandra Raymond by e mail at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this get hold of variety. There is no price tag or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally identified regulation firm with workplaces in New York and California. The organization signifies specific and institutional buyers in industrial, securities, by-product, and other elaborate litigation in condition and federal courts throughout the nation. For more information and facts about the organization, make sure you stop by www.bespc.com. Lawyer promotion. Prior benefits do not warranty equivalent outcomes.

Contacts

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Alexandra B. Raymond, Esq.

(212) 355-4648

investigations@bespc.com
www.bespc.com